Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the effects of adjunctive brexpiprazole on symptoms of irritability in patients with major depressive disorder (MDD). METHODS: Patients diagnosed with MDD according to DSM-IV-TR criteria who had inadequate response to antidepressant treatment continued treatment with their current antidepressant for 2 weeks. Patients still having inadequate response, and with irritability, received 6 weeks of open-label treatment with their current antidepressant at the same dose and adjunctive brexpiprazole (target dose: 3 mg/d). Brexpiprazole was discontinued at week 6, and the patients continued with their antidepressant until week 10. Changes from baseline to week 6 and week 6 to week 10 were analyzed. RESULTS: This study was conducted between October 7, 2013, and July 30, 2014. Fifty-four patients were treated with adjunctive brexpiprazole. At week 6, clinically relevant improvements were observed in Sheehan Irritability Scale total (-21.1) and item 1 (irritable mood) (-3.5) scores, Kellner Symptom Questionnaire total (-24.4) and anger-hostility subscale (-7.7) scores, and 30-item Inventory of Depressive Symptomatology, clinician version (IDS-C₃₀), item 6 (irritable mood) score (-1.2). More (15 patients) stopped than developed (5 patients) anger attacks during treatment, as measured by the Anger Attacks Questionnaire. The Clinical Global Impressions-Severity of Illness score improved (-1.4), as did the depressive symptoms (IDS-C₃₀ total score, -17.8; Kellner Symptom Questionnaire depression subscale score, -7.7; and Montgomery-Asberg Depression Rating Scale total score, -14.2). Irritability symptoms worsened after brexpiprazole discontinuation, assessed at week 10. Adjunctive brexpiprazole was well tolerated. CONCLUSIONS: Adjunctive treatment with brexpiprazole may represent a strategy for patients with MDD and inadequate response to antidepressant treatment who have symptoms of irritability. TRIALS REGISTRATION: ClinicalTrials.gov identifier: NCT01942785.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Brexpiprazole, was FDA approved as an adjunctive treatment to oral antidepressants in MDD based on 3 trials which showed a significant reduction in depressive symptoms (Fava et al., 2016; Thase et al., 2015a; Thase et al., 2015b).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Fava et al., 2016
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1976) · Medical Entomology and Zoology · Cited by 8,899
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., Ito, N., McQuade, R. D., Mørk, A., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213793 · Cited by 372
Wang, L. Y., Shofer, J. B., Rohde, K., Hart, K. L., Hoff, D. J., McFall, Y. H., Raskind, M. A., & Peskind, E. R. (2009) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181ab8c61 · Cited by 209
Fava, M., Hwang, I., Rush, A. J., Sampson, N., Walters, E. E., & Kessler, R. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.20 · Cited by 201
Fava, G. A., & Bech, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000441244 · Cited by 176
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Zhang, P., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09689 · Cited by 165
Chandler, G. M., Iosifescu, D. V., Pollack, M. H., Targum, S. D., & Fava, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00102.x · Cited by 158
Cited by
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Citrome, L. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12714 · Cited by 63
Benasi, G., Fava, G. A., & Rafanelli, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506110 · Cited by 45
Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders
Siwek, M., Wojtasik-Bakalarz, K., Krupa, A. J., & Chrobak, A. A. (2023) · Brain Sciences · doi:10.3390/brainsci13030397 · Cited by 50
“[57] N = 50; TRD; 6 weeks; BRX * 1–3 mg H anger in KSQ and irritability in IDS-C30; no further bouts of anger in 15 of 17 subjects; H MADRS, CGI-I, CGI-S, exacerbation after discontinuation Open-label, Davis et al.”
BackgroundBrexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
Diefenderfer, L. A., & Iuppa, C. A. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.09.207 · Cited by 44
“Evidence also shows improvements in irritability and work/school functioning with open-label brexpiprazole plus standard antidepressant treatment compared with placebo.(11,12)”
Bell, E., Boyce, P. M., Porter, R., Bryant, R. A., & Malhi, G. S. (2021) · CNS Drugs · doi:10.1007/s40263-021-00823-y · Cited by 41
“In addition to SSRIs, antipsychotics are also frequently prescribed for both major depression and bipolar disorder, and improvements in irritability scores in these populations have been found with some antipsychotics such as lurasidone and brexpiprazole [52, 100, 101].”
BackgroundBrexpiprazole for treatment-resistant major depressive disorder
Fornaro, M., Fusco, A., Anastasia, A., Cattaneo, C. I., & Berardis, D. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1654457 · Cited by 39
“Brexpiprazole showed promising efficacy among depressed patients with irritability [53,54], which may worsen or onset among several patients exposed to antidepressant monotherapy[55].”
BackgroundLurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis
Swann, A. C., Fava, M., Tsai, J., Mao, Y., Pikalov, A., & Loebel, A. D. (2017) · CNS Spectrums · doi:10.1017/s1092852917000232 · Cited by 32
Thase, M. E., Zhang, P. G. Y., Weiss, C., Meehan, S. R., & Hobart, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1638913 · Cited by 34
Clinical role of brexpiprazole in depression and schizophrenia
Parikh, N., Robinson, D., & Clayton, A. H. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s94060 · Cited by 31
Antoun, A., Girgis, E., & Mishriky, R. S. L. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000308 · Cited by 20
“Brexpiprazole (3 mg/d) was effective in the management of irritability co-morbidity with MDD as shown in changes of Sheehan irritability scale total and item 1 (irritable mood) scores (NCT01942785) (Fava et al., 2016).”
BackgroundBrexpiprazole Reduces 5-HT7 Receptor Function on Astroglial Transmission Systems
Fukuyama, K., Motomura, E., & Okada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126571 · Cited by 17
Adjunctive brexpiprazole for the treatment of major depressive disorder
Beyer, J. L., & Weisler, R. H. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1254188 · Cited by 16
Cha, D. S., Luo, X., Ahmed, J., Becirovic, L., Cha, R. H., & McIntyre, R. S. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1653759 · Cited by 13
“0001) and MADRS total score after six weeks [21,43].”
BackgroundBrexpiprazole in the Treatment of Major Depressive Disorder
Shirawi, M. I. A., Edgar, N. E., & Kennedy, S. H. (2017) · Clinical Medicine Insights Therapeutics · doi:10.1177/1179559x17731801 · Cited by 12
Pessina, E., Martini, A., Raffone, F., & Martiadis, V. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1299368 · Cited by 12
Aladeen, T. S., Westphal, E. S., Lee, Y. L., Rong, C., Rainka, M. M., Capote, H. A., & McIntyre, R. S. (2018) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12258 · Cited by 10
Carpenter, J. S., Zmicerevska, N., Crouse, J. J., Nichles, A., Garland, A., Song, Y. J. C., Wilson, C. E., Rohleder, C., McHugh, C. M., Leweke, F. M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-056298 · Cited by 5
Kapadia, S., Zhang, Z., Ardic, F. C., Patel, M., Thase, M. E., & Papakostas, G. I. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf074 · Cited by 2
“35,36 37-40 In terms of safety, there were no notable differences in the incidence of TEAEs for adjunctive brexpiprazole when stratified by degree of response to antidepressant treatment.”
Simutkin, G. G. (2018) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2018-3-10-21 · Cited by 2
When an Antipsychotic Working as an Antidepressant, Do They Have a Therapeutic Window?
Aydın, İ. H., Salifu, A., Settle, K., & El‐Mallakh, R. S. (2025) · Annals of Clinical Psychiatry · doi:10.1177/10401237251344096 · Cited by 2
Defining irritability as a diagnostic marker and a target for responsiveness
Bell, E., & Malhi, G. S. (2020) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2020.100067 · Cited by 1
Çifteci, K., Yılmaz, H., Nas, B., Karatepe, H. T., Elbay, R. Y., Turgal, E., & Karadere, M. E. (2026) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2026.2706181
Severtson, S. G., Boskovic, D. H., Eisenberg, D. F., Ardic, F. C., Abdrabboh, A., & Marci, C. D. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-01028-5
Metadata
- Authors
- Fava, M., Ménard, F., Davidsen, C. K., & Baker, R. A.
- Affiliations
- Lundbeck (Denmark) (DK)
- Otsuka (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2016-07-05
- Volume
- 77
- Issue
- 12
- Pages
- 1695-1701
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2460591166
- Cited by
- 23
- References
- 23
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 1
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- brexpiprazole, major depressive disorder, irritability, adjunctive therapy, inadequate response to antidepressants, irritable mood, anger attacks, antidepressant non-response, treatment discontinuation
- MeSH terms
- Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Irritable Mood, Male, Middle Aged, Thiophenes, Quinolones, Outcome Assessment, Health Care, Serotonin Agents, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.